BENICAR HCT Rx
Generic Name and Formulations:
Olmesartan medoxomil, hydrochlorothiazide; 20mg/12.5mg, 40mg/12.5mg, 40mg/25mg; tabs.
Indications for BENICAR HCT:
Not for initial therapy. May be substituted for titrated components. Individualize. ≥18yrs: BP not controlled on olmesartan alone: initially 40/12.5mg once daily. Intolerant to or BP not controlled on HCTZ alone: initially 20/12.5mg once daily. Both: may titrate at 2–4 week intervals up to max 40mg/25mg once daily. Severe renal impairment (CrCl ≤30mL/min): not recommended. Volume depleted: reduce dose.
<18yrs: not established.
Anuria. Sulfonamide allergy. Concomitant aliskiren in patients with diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Correct salt/volume depletion before starting, or monitor closely. Renal impairment: monitor for worsening renal function. Hepatic dysfunction. Renal artery stenosis. Possibly less effective in black patients. Severe CHF. Asthma. Diabetes. Postsympathectomy. SLE. Gout. Monitor electrolytes. Acute myopia. Secondary angle-closure glaucoma. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
Angiotensin II receptor blocker (ARB) + thiazide diuretic.
Digitalis, lithium toxicity. Adjust antidiabetic, antigout medications. ACTH, corticosteroids increase hypokalemia risk. Orthostatic hypotension potentiated by alcohol, CNS depressants, barbiturates, narcotics. Potentiates other antihypertensives. May potentiate nondepolarizing muscle relaxants. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. May antagonize norepinephrine. May be antagonized by, and renal toxicity potentiated by NSAIDs, including COX-2 inhibitors; monitor renal function periodically in elderly and/or volume depleted. May interfere with parathyroid tests. Reduced absorption with cholestyramine, colestipol. Take 4hrs before colesevelam HCl dose.
Dizziness, infection, hyperuricemia, nausea, back pain, weakness, orthostatic hypotension, electrolyte disturbances, rash, adverse lipid values, possible sprue-like enteropathy, rhabdomyolysis (rare).
Tabs—30, 90, 1000
Sign Up for Free e-newsletters
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- The Caregivers' Cancer Journey
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
- Survey of ACEP Councilors Reveals NP, PA Staffing Models, Practice Patterns Vary
- Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer
- Genetic Susceptibility to Pancreatic Cancer Linked to 6 Specific Gene Mutations
- Dinner Hour and Sleep Habits Affect Risk of Breast, Prostate Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|